News

ABBV-951, an under-the-skin formulation of levodopa/carbidopa, outperformed the standard oral therapy at controlling Parkinson’s symptoms in advanced disease patients in a Phase 3 clinical trial, top-line results show. “These data are promising and demonstrate positive results on a key endpoint used to assess efficacy of treatments for patients with…

Fascinate Therapeutics has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KM-819 as a potential therapy for Parkinson’s disease, the company announced in a press release. Parkinson’s disease is characterized by the death and dysfunction…

The U.S. Food and Drug Administration has approved Insightec’s incision-free brain “surgery” technology — Exablate Neuro — for the treatment of motor symptoms in Parkinson’s disease patients. According to the company, the device is indicated to use in patients with moderate-to-severe motor complications, such as tremors, stiffness and uncontrolled, involuntary movement…

Those attending The Michael J. Fox Foundation’s (MJFF) “A Funny Thing Happened on the Way to Cure Parkinson’s” annual fundraiser got to hear from the organization’s founder, Michael J. Fox. Nearly 700 supporters converged on the Jazz at Lincoln Center in New York City recently to celebrate the…

A specific genetic variant, or mutation, that is associated with an increased risk of developing amyotrophic lateral sclerosis (ALS) may also raise a person’s risk of Parkinson’s disease, a study reported. Shared features of both these neurodegenerative disorders include causative processes and “genetic backgrounds,” the researchers noted, suggesting that a mutation affecting…

Jubilee BioTech has developed JUBIwatch, a new device intended to improve patients’ medication adherence — taking medicines at the right time with the right dose. Under development by the startup South Korean company for the past two years, JUBIwatch is a smart watch and medication management platform that uses microneedles…

Clinical trials will begin soon in China to evaluate Luye Pharma’s LY03009, a once-a-month, extended-release investigational therapy to treat people with Parkinson’s disease.  A Phase 1 safety trial is underway in Australia, and the company said…

A team of researchers at Caltech will be looking into the interactions between the brain and the gut in Parkinson’s, in the hope of uncovering how their interaction may affect the disease. Studies are noting abnormalities in the gastrointestinal environment of Parkinson’s patients, and a better understanding of “gut-brain connections”…

Deep brain stimulation (DBS) in adults with early Parkinson’s reduces disease-specific medication use and provides significant cost savings, for up to 15 years, relative to standard care, a study shows. While these savings — just over $100,000 over 15 years — did not outweigh the costs of the surgical…

The launch of a Phase 2 trial into the safety and early efficacy of oral NE3107 in treating Parkinson’s disease patients with motor fluctuations while on levodopa was approved by the U.S. Food and Drug Administration (FDA), BioVie, the therapy’s developer, announced. BioVie plans to initiate patient enrollment for the trial,…